Catheter Precision Inc. Cash Flow Conversion Efficiency
Catheter Precision Inc. cash flow conversion efficiency. Based on the latest financial reports, Catheter Precision Inc. (VTAK) has a cash flow conversion efficiency ratio of -0.227x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.51 Million) by net assets ($6.65 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Catheter Precision Inc. (2016–2025)
Cash flow conversion efficiency of Catheter Precision Inc. from 2016 to 2025. This chart illustrates how Catheter Precision Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View Catheter Precision Inc. stock quote for real-time trading data and today's change.
Catheter Precision Inc. Cash Flow Conversion Ratio Explained
Catheter Precision Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Catheter Precision Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Catheter Precision Inc. ranked by their cash flow conversion efficiency. Also see VTAK stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Himalaya Energi Perkasa Tbk PT
JK:HADE
|
-0.012x |
|
Invion Ltd
AU:IVX
|
-0.163x |
|
Cyclerion Therapeutics Inc
NASDAQ:CYCN
|
-0.282x |
|
The Income & Growth VCT
LSE:IGV
|
-0.016x |
|
Nanocap Group AB Series B
ST:NANOC-B
|
N/A |
|
Crown LNG Holdings Limited Warrants
NASDAQ:CGBSW
|
-0.192x |
|
PREMIA FINANCE O.N.
F:81U
|
N/A |
|
Cosmo Metals Ltd
AU:CMO
|
-0.018x |
Annual Cash Flow Conversion Efficiency for Catheter Precision Inc. (2016–2025)
The table below shows the annual cash flow conversion efficiency of Catheter Precision Inc. from 2016 to 2025. Review Catheter Precision Inc. free cash flow to debt ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $6.65 Million | $-8.30 Million | -1.247x | -58.18% |
| 2024-12-31 | $11.76 Million | $-9.27 Million | -0.789x | +18.95% |
| 2023-12-31 | $21.19 Million | $-20.62 Million | -0.973x | +60.08% |
| 2022-12-31 | $9.26 Million | $-22.57 Million | -2.437x | -20.63% |
| 2021-12-31 | $13.67 Million | $-27.62 Million | -2.020x | -50.95% |
| 2020-12-31 | $21.15 Million | $-28.30 Million | -1.338x | -33.75% |
| 2019-12-31 | $33.15 Million | $-33.17 Million | -1.001x | -260.66% |
| 2018-12-31 | $66.70 Million | $-18.51 Million | -0.277x | -138.26% |
| 2017-12-31 | $-7.62 Million | $-5.52 Million | 0.725x | -85.39% |
| 2016-12-31 | $-380.00K | $-1.89 Million | 4.963x | -- |
About Catheter Precision Inc.
Catheter Precision, Inc. designs, manufactures, and sells medical technologies for the field of cardiac electrophysiology (EP) in the United States and Europe. The company's lead product is View into Ventricular Onset System, a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally … Read more